Measuring and strengthening immunity to measles in young adults fully immunised in childhood - single arm challenge study

Not Applicable

• Conditions: Waning measles immunity in vaccinated young adults; Inflammatory and Immune System - Normal development and function of the immune system; Immune health; Public Health - Other public health

• Registration Number: ACTRN12623000137695
• Lead Sponsor: niversity of Otago

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-02-09
• Last Update Posted: 13 February 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

*Seropositive: Antibody above threshold for positivity of the Diasorin or BioPlex assay (for Dunedin and Auckland diagnostic labs, respectively) for both of measles and mumps antibodies and not required to have a dose of MMR vaccine by University of Otago or University of Auckland Screening and Immunisation Policies
*Capable and willing to give written informed consent
*Residing in Dunedin or Auckland
*Able and willing to participate for the duration of the study visits and follow-up
*Willing to provide verifiable identification at study entry and follow-up visits
*Daily access to an internet-connected device (smart phone, tablet, laptop or PC) and willing to complete an electronic diary post vaccination.

Exclusion Criteria

Contraindications to MMR as specified in the NZ Immunisation Handbook. These include:
•proven anaphylaxis to the vaccine or vaccine component (eg, neomycin or gelatin)
•significant immunocompromise: impaired cell-mediated immunity, including untreated malignancy, type 1 interferon receptor (IFNAR) signalling pathway defects, immunosuppressive drug therapy, including high-dose steroids, receiving high-dose radiotherapy, HIV infection with severely impaired T cell immunity
•another live vaccine, including Bacillus Calmette-Guérin (BCG), within the previous 4 weeks
•pregnant women – pregnancy should be avoided for four weeks after immunization
•participants pregnant during study participation may complete follow-up.
•intravenous immunoglobulin or blood transfusion during the preceding 11 months

Study & Design

• Study Type: Interventional
• Study Design: Not specified